Literature DB >> 10699069

Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.

N Wolmark1, H S Wieand, D M Hyams, L Colangelo, N V Dimitrov, E H Romond, M Wexler, D Prager, A B Cruz, P H Gordon, N J Petrelli, M Deutsch, E Mamounas, D L Wickerham, E R Fisher, H Rockette, B Fisher.   

Abstract

BACKGROUND: The conviction that postoperative radiotherapy and chemotherapy represent an acceptable standard of care for patients with Dukes' B (stage II) and Dukes' C (stage III) carcinoma of the rectum evolved in the absence of data from clinical trials designed to determine whether the addition of radiotherapy results in improved disease-free survival and overall survival. This study was carried out to address this issue. An additional aim was to determine whether leucovorin (LV)-modulated 5-fluorouracil (5-FU) is superior to the combination of 5-FU, semustine, and vincristine (MOF) in men. PATIENTS AND METHODS: Eligible patients (n = 694) with Dukes' B or C carcinoma of the rectum were enrolled in National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol R-02 from September 1987 through December 1992 and were followed. They were randomly assigned to receive either postoperative adjuvant chemotherapy alone (n = 348) or chemotherapy with postoperative radiotherapy (n = 346). All female patients (n = 287) received 5-FU plus LV chemotherapy; male patients received either MOF (n = 207) or 5-FU plus LV (n = 200). Primary analyses were carried out by use of a stratified log-rank statistic; P values are two-sided.
RESULTS: The average time on study for surviving patients is 93 months as of September 30, 1998. Postoperative radiotherapy resulted in no beneficial effect on disease-free survival (P =.90) or overall survival (P =.89), regardless of which chemotherapy was utilized, although it reduced the cumulative incidence of locoregional relapse from 13% to 8% at 5-year follow-up (P =.02). Male patients who received 5-FU plus LV demonstrated a statistically significant benefit in disease-free survival at 5 years compared with those who received MOF (55% versus 47%; P =.009) but not in 5-year overall survival (65% versus 62%; P =.17).
CONCLUSIONS: The addition of postoperative radiation therapy to chemotherapy in Dukes' B and C rectal cancer did not alter the subsequent incidence of distant disease, although there was a reduction in locoregional relapse when compared with chemotherapy alone.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10699069     DOI: 10.1093/jnci/92.5.388

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  97 in total

1.  Evaluating toxicity in neoadjuvant radio-chemotherapy of rectal cancer.

Authors:  Stefan Höcht
Journal:  Int J Colorectal Dis       Date:  2003-07-15       Impact factor: 2.571

2.  [Principles of postoperative therapy in rectal carcinoma].

Authors:  G Folprecht; C-H Köhne
Journal:  Chirurg       Date:  2004-01       Impact factor: 0.955

3.  Adjuvant radiotherapy following total mesorectal excision for stage IIA rectal cancer: is it beneficial?

Authors:  Jin Soo Kim; Nam Kyu Kim; Byung Soh Min; Hyuk Hur; Joong Bae Ahn; Ki Chang Keum
Journal:  Int J Colorectal Dis       Date:  2010-06-11       Impact factor: 2.571

4.  Routine preventive care and cancer surveillance in long-term survivors of colorectal cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol LTS-01.

Authors:  Hiroko Kunitake; Ping Zheng; Greg Yothers; Stephanie R Land; Louis Fehrenbacher; Jeffrey K Giguere; D Lawrence Wickerham; Lawrence Wickerham; Patricia A Ganz; Clifford Y Ko
Journal:  J Clin Oncol       Date:  2010-11-15       Impact factor: 44.544

Review 5.  Rectal cancer treatment: improving the picture.

Authors:  Juan A Diaz-Gonzalez; Leire Arbea; Javier Aristu
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

6.  Feasibility of adequate resectable rectal cancer treatment in a third-level hospital.

Authors:  J Gallego-Plazas; F Menárguez-Pina; A Maestre-Peiró; V González-Orozco; F Andreu; M J Escudero-Barea; M A Morcillo
Journal:  Clin Transl Oncol       Date:  2009-03       Impact factor: 3.405

7.  Stage-specific survival differences associated with postoperative radiotherapy for gastrointestinal cancers.

Authors:  John S Moody; Stephen M Sawrie; Kevin R Kozak; John P Plastaras; George Howard; James A Bonner
Journal:  J Gastrointest Cancer       Date:  2009-03-18

8.  Adjuvant therapy for rectal cancer.

Authors:  Smitha S Krishnamurthi; Yuji Seo; Timothy J Kinsella
Journal:  Clin Colon Rectal Surg       Date:  2007-08

9.  Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course.

Authors:  Michael P Herman; Scott Kopetz; Priya R Bhosale; Cathy Eng; John M Skibber; Miguel A Rodriguez-Bigas; Barry W Feig; George J Chang; Marc E Delclos; Sunil Krishnan; Christopher H Crane; Prajnan Das
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-01-13       Impact factor: 7.038

10.  Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.

Authors:  Mark S Roh; Linda H Colangelo; Michael J O'Connell; Greg Yothers; Melvin Deutsch; Carmen J Allegra; Morton S Kahlenberg; Luis Baez-Diaz; Carol S Ursiny; Nicholas J Petrelli; Norman Wolmark
Journal:  J Clin Oncol       Date:  2009-09-21       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.